Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRalphaDC Vaccine in Advanced Ovarian Cancer
NCT02111941Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Apr 2014
- Primary completion
- Jul 2021
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Multi-epitope folate receptor alpha-loaded dendritic cell vaccine in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Mayo Clinic. Primary endpoint: Incidence of Dose-Limiting Toxicities at 3 weeks. Started Apr 2014; status: completed.
02
Drugs
Multi-epitope folate receptor alpha-loaded dendritic cell vaccine
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02111941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02111941.